Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 Study.

HIV MSM chemsex high-risk sexual behaviors sexualized drug use sexually transmitted infections

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
24 Nov 2023
Historique:
received: 28 08 2023
revised: 04 11 2023
accepted: 12 11 2023
medline: 9 12 2023
pubmed: 9 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

Sexualized drug use (SDU) has become a public health concern in recent years. This study aimed to estimate the prevalence of SDU in gay, bisexual, and other men who have sex with men living with HIV (HIV + GBMSM) in Madrid during 2019/2020 and compare it with data from 2016/2017 in order to detect changes in patterns. We analyzed the frequency of SDU in a sample of HIV + GBMSM attending HIV clinics, who participated in an anonymous online survey regarding sexual behavior and recreational drug use. The association between SDU, sexual risk behaviors, and STIs was evaluated. This study included 424 HIV + GBMSM, with a mean age of 40 (10.43) years. Overall, 94% (396) reported being sexually active. Additionally, 33% (140) had been diagnosed with an STI within the previous year. Moreover, 54% (229) had used drugs in the last year, 25% (107) engaged in SDU, and 16% (17) reported engagement in slamsex. After adjusting for confounding factors, SDU was associated with STIs, fisting, unprotected anal intercourse, and having >24 sexual partners in the last year. According to the DUDIT test scores, 80% (81) probably had problematic drug use (≥6 points), and 8% (8) probable drug dependence (≥25 points). When comparing the U-SEX-1 (2016/2017) data with the U-SEX-2 (2019/2020) data, no significant differences were found in the proportion of participants practicing SDU or slamming. The prevalence of SDU among HIV + GBMSM has remained high in recent years and without significant changes. The risk of problematic drug use among those who practice SDU is high. We observed a clear association between SDU, high-risk sexual behaviors, and STIs.

Sections du résumé

BACKGROUND BACKGROUND
Sexualized drug use (SDU) has become a public health concern in recent years. This study aimed to estimate the prevalence of SDU in gay, bisexual, and other men who have sex with men living with HIV (HIV + GBMSM) in Madrid during 2019/2020 and compare it with data from 2016/2017 in order to detect changes in patterns.
METHODS METHODS
We analyzed the frequency of SDU in a sample of HIV + GBMSM attending HIV clinics, who participated in an anonymous online survey regarding sexual behavior and recreational drug use. The association between SDU, sexual risk behaviors, and STIs was evaluated.
RESULTS RESULTS
This study included 424 HIV + GBMSM, with a mean age of 40 (10.43) years. Overall, 94% (396) reported being sexually active. Additionally, 33% (140) had been diagnosed with an STI within the previous year. Moreover, 54% (229) had used drugs in the last year, 25% (107) engaged in SDU, and 16% (17) reported engagement in slamsex. After adjusting for confounding factors, SDU was associated with STIs, fisting, unprotected anal intercourse, and having >24 sexual partners in the last year. According to the DUDIT test scores, 80% (81) probably had problematic drug use (≥6 points), and 8% (8) probable drug dependence (≥25 points). When comparing the U-SEX-1 (2016/2017) data with the U-SEX-2 (2019/2020) data, no significant differences were found in the proportion of participants practicing SDU or slamming.
CONCLUSIONS CONCLUSIONS
The prevalence of SDU among HIV + GBMSM has remained high in recent years and without significant changes. The risk of problematic drug use among those who practice SDU is high. We observed a clear association between SDU, high-risk sexual behaviors, and STIs.

Identifiants

pubmed: 38068345
pii: jcm12237293
doi: 10.3390/jcm12237293
pmc: PMC10707460
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Gilead Sciences (Spain)
ID : IN-ES-987-5391

Références

Adicciones. 2011;23(3):249-55
pubmed: 21814713
Int J Drug Policy. 2015 Dec;26(12):1171-6
pubmed: 26298332
PLoS Med. 2021 Jun 18;18(6):e1003677
pubmed: 34143781
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Int J Drug Policy. 2019 Jun;68:54-61
pubmed: 30999243
AIDS Patient Care STDS. 2018 Mar;32(3):112-118
pubmed: 29620925
BMJ. 2015 Nov 03;351:h5790
pubmed: 26537832
Int J Drug Policy. 2017 May;43:33-43
pubmed: 28189979
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
HIV Med. 2018 Apr;19(4):261-270
pubmed: 29368440
Int J Drug Policy. 2016 Dec;38:4-12
pubmed: 27788450
Int J STD AIDS. 2017 Mar;28(4):362-366
pubmed: 27178067
J Clin Med. 2021 Apr 13;10(8):
pubmed: 33924530
Sex Health. 2022 Dec;19(6):566-573
pubmed: 36154675
Harm Reduct J. 2023 Apr 16;20(1):52
pubmed: 37062840
PLoS One. 2019 Dec 4;14(12):e0220272
pubmed: 31800575
Int J STD AIDS. 2023 Jun 6;:9564624231180781
pubmed: 37279926
Int J Drug Policy. 2017 Nov;49:24-25
pubmed: 28873358
Curr Opin Infect Dis. 2016 Feb;29(1):58-63
pubmed: 26694620
Sex Transm Infect. 2015 Dec;91(8):564-8
pubmed: 26163510
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
Int J Drug Policy. 2018 May;55:131-148
pubmed: 29625796
Acta Psychiatr Scand. 2003 Mar;107(3):216-21
pubmed: 12580829
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):349-55
pubmed: 19387357
JAMA. 2020 Aug 18;324(7):682-699
pubmed: 32809007
Int J Environ Res Public Health. 2021 Dec 17;18(24):
pubmed: 34948907

Auteurs

Pablo Ryan (P)

Internal Medicine and HIV Unit, Infanta Leonor University Hospital, 28031 Madrid, Spain.
Department of Medicine, Medicine Faculty, Complutense University of Madrid (UCM), 28040 Madrid, Spain.
Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Helen Dolengevich-Segal (H)

Dual Pathology Program, Henares Hospital, 28822 Coslada, Spain.
Department of Psychiatry, Francisco de Vitoria University, 28822 Madrid, Spain.

Luis Ramos-Ruperto (L)

Infectious Diseases and HIV Unit, La Paz University Hospital, IdiPAZ, 28046 Madrid, Spain.

Alfonso Cabello (A)

Infectious Diseases and HIV Unit, Hospital Universitario Fundación Jimenez Diaz y IIS-FJD, 28040 Madrid, Spain.
Department of Biological and Health Psychology, Autonomous University of Madrid (UAM), 28049 Madrid, Spain.

Matilde Sanchez-Conde (M)

Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.
Infectious Diseases and HIV Unit, Ramon y Cajal University Hospital, 28034 Madrid, Spain.

Jorge Vergas (J)

Internal Medicine Department, San Carlos University Hospital, 28040 Madrid, Spain.

Jorge Valencia (J)

Internal Medicine and HIV Unit, Infanta Leonor University Hospital, 28031 Madrid, Spain.
Harm Reduction Unit "SMASD", 28020 Madrid, Spain.

Guillermo Cuevas (G)

Internal Medicine and HIV Unit, Infanta Leonor University Hospital, 28031 Madrid, Spain.

José Sanz (J)

Internal Medicine, Alcalá University Hospital, 28805 Madrid, Spain.

Javier Curto-Ramos (J)

Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital, 28046 Madrid, Spain.

Javier Pérez-Bootello (J)

Dermatology Service, Ramon y Cajal University Hospital, 28034 Madrid, Spain.

Jorge Naharro-Rodriguez (J)

Dermatology Service, Ramon y Cajal University Hospital, 28034 Madrid, Spain.

Mar J F Ollero (MJF)

Department of Biological and Health Psychology, Autonomous University of Madrid (UAM), 28049 Madrid, Spain.

Lucio Garcia Fraile (L)

Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.
Internal Medicine and HIV Unit, La Princesa University Hospital, 28006 Madrid, Spain.

Leire Pérez-Latorre (L)

Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.
HIV Unit, Gregorio Marañon University Hospital and IiSGM, 28009 Madrid, Spain.

Otilia Bisbal (O)

Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.
Internal Medicine and HIV Unit, 12 de Octubre University Hospital, 28041 Madrid, Spain.

Sara De la Fuente (S)

Internal Medicine and HIV Unit, Puerta del Hierro University Hospital, 28222 Majadahonda, Spain.

Juan Emilio Losa (JE)

Infectious Diseases, Fundación Alcorcón University Hospital, 28922 Alcorcón, Spain.

Miguel Cervero (M)

Internal Medicine, Severo Ochoa University Hospital, 28914 Leganes, Spain.

Miriam Estebanez (M)

Infectious Diseases and HIV Unit, Gómez Ulla University Hospital, 28047 Madrid, Spain.

Inés Suarez-Garcia (I)

Biomedical Research Network Center in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28034 Madrid, Spain.
Internal Medicine, Infanta Sofia University Hospital, Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Sofía y Hospital Universitario del Henares (FIIB HUIS HHEN), 28702 San Sebastian de los Reyes, Spain.
Department of Medicine, Medicine Faculty, European University, 28032 Madrid, Spain.

Alejandra Gimeno (A)

Internal Medicine, Torrejón University Hospital, 28850 Torrejón de Ardoz, Spain.

Ignacio Terrancle (I)

Internal Medicine, Tajo University Hospital, 28670 Aranjuez, Spain.

Rafael Mican (R)

Infectious Diseases and HIV Unit, La Paz University Hospital, IdiPAZ, 28046 Madrid, Spain.

Alicia González-Baeza (A)

Department of Biological and Health Psychology, Autonomous University of Madrid (UAM), 28049 Madrid, Spain.

Classifications MeSH